GlassScriptPhysician profile
Anthony Floyd Collins
NPI 1851358774
$6,731.27
in general payments reported to CMS, 2019-2025
51 companies · $993 in 2025
The $993 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $888 · 2020: $479 · 2021: $627 · 2022: $1,334 · 2023: $1,076 · 2024: $1,335 · 2025: $993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,203 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,203.02 |
| Education | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $998.56 | 2021-2025 | Qulipta, Botox, Duopa |
| Novartis Pharmaceuticals Corporation | $541.71 | 2019-2025 | |
| Ucb, INC. | $536.89 | 2019-2025 | Zilbrysq, Rystiggo, Briviact |
| Alexion Pharmaceuticals, INC. | $429.84 | 2019-2024 | Ultomiris, Soliris |
| Lilly USA, LLC | $350.31 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Biogen, INC. | $252.71 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Janssen Pharmaceuticals, INC | $235.08 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $230.12 | 2019-2024 | Ajovy, Austedo Xr, Austedo |
| Sk Life Science, INC. | $209.81 | 2020-2024 | |
| Neurocrine Biosciences, INC. | $206.78 | 2019-2024 | Ingrezza, Ongentys |
| Argenx US, INC. | $206.75 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Jazz Pharmaceuticals INC. | $204.79 | 2019-2025 | Epidiolex |
| Lundbeck LLC | $162.47 | 2023-2025 | Vyepti, Rexulti |
| Eisai INC. | $157.94 | 2020-2025 | |
| Avion Pharmaceuticals | $131.75 | 2022-2023 | Dhivy |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.